Novo Nordisk, struggling to meet weight-loss drug demand, to buy facilities in three-way deal
The controlling shareholder of weight-loss drug maker Novo Nordisk on Monday said it’s buying a provider of drug manufacturing for $16.5 billion, and will then sell three key facilities to Europe’s largest company by market cap. Novo Holdings, the controlling shareholder of Novo Nordisk NVO, ,…
#novonordisk #novoholdings #novonordisknvo #catalentctlt #catalent #copenhagennovob #novo #anagni #bloomington #ind
